MRC/ABPI COPD Consortium Work Package 1: COPD Phenotyping

MRC/ABPI COPD 联盟工作包 1：COPD 表型分析

• 批准号: G1001365/1
• 负责人: Christopher Brightling
• 金额: $ 431.08万
• 依托单位: University of Leicester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001365%2F1
• 关键词: MRC; ABPI; COPD; Consortium; Work

COPD (which used to be called chronic bronchitis and emphysema) is a common disease which causes considerable difficulty to sufferers. The pharmaceutical industry has been relatively unsuccessful in bringing new treatments to the marketplace for COPD, with many products failing when they are first given to patients. This is largely because not all COPD sufferers are the same and it is likely that drugs will treat certain aspects of the disease and therefore are more likely to benefit some but not all patients. We propose to try to understand what makes people with COPD different from each other and to use these differences to further our understanding of which types of drugs will benefit which types of people. Using this approach we aim to identify markers in blood and sputum that will help us to predict the progression of COPD and response to therapy.

COPD（过去称为慢性支气管炎和肺气肿）是一种常见疾病，给患者带来很大的困扰。制药行业在将慢性阻塞性肺病新疗法推向市场方面相对不成功，许多产品在首次提供给患者时都失败了。这主要是因为并非所有慢性阻塞性肺病患者都是一样的，并且药物可能会治疗该疾病的某些方面，因此更有可能使部分而非所有患者受益。我们建议尝试了解慢性阻塞性肺病患者之间的差异，并利用这些差异进一步了解哪些类型的药物将有益于哪些类型的人。使用这种方法，我们的目标是识别血液和痰液中的标记物，这将帮助我们预测慢性阻塞性肺病的进展和对治疗的反应。